Amoéba
ALMIB | PA
Overview
Corporate Details
- ISIN(s):
- FR0011051598 (+2 more)
- LEI:
- 9695005QNE7C8Z0LXU64
- Country:
- France
- Address:
- 38 AVENUE DES FRERES MONTGOLFIER, 69680 CHASSIEU
- Website:
- https://amoeba-nature.com/en/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Amoéba is a greentech company that develops and commercializes solutions for managing microbiological risk based on the patented use of a biological agent derived from the amoeba *Willaertia magna*. The company's primary focus is on two key global markets: agricultural biocontrol and cosmetics. For the plant protection sector, its technology offers a natural, fungicidal alternative to chemical treatments against diseases like mildew and rust. For the cosmetics industry, it provides a natural active ingredient. Amoéba's technology has also shown potential applications in water treatment and wound care. Founded in 2010, the company is transitioning from research and development to an industrial and commercial-scale entity.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Amoéba.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-22 18:25 |
Share Issue/Capital Change
Amoéba launches a capital increase open to all to support its industrial and co…
|
English | 418.9 KB | |
| 2025-07-22 17:45 |
Regulatory News Service
Amoéba signs an agreement with Metron Technology, a subsidiary of Oriental Beau…
|
English | 348.1 KB | |
| 2025-07-22 17:45 |
M&A Activity
Amoéba signe un accord avec Metron Technology, filiale du groupe Oriental Beaut…
|
French | 345.8 KB | |
| 2025-06-17 18:00 |
Regulatory News Service
Amoéba takes another decisive step forward with the final approval of its bioco…
|
English | 391.5 KB | |
| 2025-06-17 18:00 |
Regulatory News Service
Amoéba franchit une nouvelle étape décisive avec l'approbation définitive de sa…
|
French | 387.4 KB | |
| 2025-06-03 17:45 |
Regulatory News Service
Koppert et Amoéba signent un accord de distribution majeur pour une solution bi…
|
French | 191.6 KB | |
| 2025-06-03 17:45 |
Regulatory News Service
Koppert and Amoéba sign major distribution agreement for innovative biofungicid…
|
English | 170.4 KB | |
| 2025-05-22 18:00 |
Report Publication Announcement
Amoéba: Ordinary and Extraordinary General Meeting of 26 June 2025
|
English | 332.5 KB | |
| 2025-05-22 18:00 |
Pre-Annual General Meeting Information
Amoéba : Assemblée Générale Ordinaire et Extraordinaire du 26 juin 2025
|
French | 331.8 KB | |
| 2025-05-21 18:00 |
Regulatory News Service
A new milestone towards the market launch of AXPERA: EU Member States unanimous…
|
English | 375.5 KB | |
| 2025-05-21 18:00 |
Regulatory News Service
Nouvelle étape franchie vers la mise sur le marché d'AXPERA : vote à l'unanimit…
|
French | 372.5 KB | |
| 2025-05-20 19:00 |
Board/Management Information
Amoéba announces the nomination of Charlotte Franceries, a leading figure in th…
|
English | 339.5 KB | |
| 2025-05-20 19:00 |
Board/Management Information
Amoéba annonce l'arrivée au sein de son Conseil d'administration de Charlotte F…
|
French | 352.3 KB | |
| 2025-05-12 18:00 |
M&A Activity
Amoéba et Koppert continuent de préparer le lancement commercial d'AXPERA, le p…
|
French | 325.9 KB | |
| 2025-05-12 18:00 |
Regulatory News Service
Amoéba and Koppert continue to prepare the commercial launch of AXPERA, the bio…
|
English | 328.8 KB |
Automate Your Workflow. Get a real-time feed of all Amoéba filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Amoéba via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-08-08 | N/A | Other | Buy | 9,260 | 4,900.39 EUR |
| 2024-08-07 | N/A | Other | Buy | 17,556 | 8,943.03 EUR |
| 2024-08-06 | N/A | Other | Buy | 4,874 | 2,252.76 EUR |
| 2024-08-05 | N/A | Other | Buy | 16,517 | 7,295.56 EUR |
| 2024-07-31 | N/A | Other | Buy | 58,309 | 26,868.79 EUR |
| 2024-07-30 | N/A | Other | Buy | 6,197 | 2,701.27 EUR |
| 2024-07-29 | N/A | Other | Buy | 7,404 | 3,253.32 EUR |
| 2024-07-18 | N/A | Other | Buy | 13,437 | 6,167.58 EUR |
| 2024-07-17 | N/A | Other | Buy | 200 | 92.70 EUR |
| 2024-07-16 | N/A | Other | Buy | 3,565 | 1,620.29 EUR |
